

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC20170003305 Fecha de prioridad: 15 de octubre de 2014				
CRITERIOS PARA LA BÚSQUEDA				
Palabras clave utilizadas		([pyridin-3-yl]-2,3-dihydro- benzo[1,4]dioxine-5-carboxylic AND acid) AND (inhibitors of aldosterone synthase (CYP11B2)) AND (renal OR diabetic OR nephropathy OR cardiovascular OR fibrotic)		
		Pyridin AND benzo[1,4]dioxine AND (aldosterone OR CYP11B2) AND (renal OR diabetic OR nephropathy OR cardiovascular OR fibrotic)		
		Pyridin AND benzo[1,4]dioxine AND aldosterone		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07D 405/14, C07D 413/14, C07D 405/04, C07D 417/14, A61P 13/12, A61P 9/12, A61P 9/10, A61K 31/43		
DOCUMENTOS CONSIDERADOS RELEVANTES				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	Ninguna	---	---	---
ISA/IPEA (EPO US) Espacenet	US20100292225	18/11/2010	---	---
	WO2014055595	10/04/2014	---	---
	S. Lucas et al, J Med Chem, 51, 8077-8087 (2008)	2008	---	A
	WO2010042477	15/04/2010	---	A
	WO2006044556	27/04/2006		A
USPTO	Ninguna	---	---	A
Patbase	WO2010007046	21/01/2010	---	A
	WO201045251	22/04/2010	---	A
Google Patents	EP2429995B1	22/01/2014	---	A
Orbit	WO2010045251	22/04/2010	---	A
	WO2007117559	18/10/2007	---	A
	WO2004089415	21/10/2004	---	A
EPOQUE	US20100292225	18/11/2010	---	A
STN	Ninguna	---	---	---
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado.		
		“Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente

**Se incluye entre otros, toda la referencia de la literatura no patente.

Fecha del reporte de búsqueda:

27 de agosto de 2018

SIPI:

Título/Denominación	Piridin AND benzo[1,4]dioxin AND aldosterona		
Referencia del solicitante		Tipo de solicitud	
Fecha de radicación	Advertencia(s) Su búsqueda no produjo resultados. Ok		
Decision Date_ES			



Menu - Search - History - Session - Folder - Order - Help - Logoff

Search 2: STAC=(Pyridin AND benzo[1,4]dioxine AND (aldosterone OR CYP11B2) AND (renal OR diabetic OR nephropathy OR cardiovascular OR fibrotic))
Results 1

Explore search

#	Search query	Results	Options
2	STAC=(Pyridin AND benzo[1, 4]dioxine AND (aldosterone OR CYP11B2) AND (renal OR diabetic OR nephropathy OR cardiovascular OR fibrotic))	1	View Browse Hits Optimise more...
1	STAC=(Pyridine AND benzo[1, 4]dioxine AND (aldosterone OR CYP11B2) AND (renal OR diabetic OR nephropathy OR cardiovascular OR fibrotic))	1	View Browse Hits Optimise more...

Aldosterone synthase inhibitors



www.google.com.co/patents/US20160108026 - Traducir esta página

Solicitud - Presentada el 14/10/2015 - Publicada el 21/04/2016 - Keith R. Hornberger -

Boehringer Ingelheim International GmbH

2-Pyridin-3-yl-2,3-dihydro- benzo[1,4]dioxine-5-carboxylic acid amide enantiomer A (35 mg, 0.10 mmol) in 2.0 mL of 1,4-dioxane is added pyridine (0.16 mL, ...

[Descripción general](#) · [Información relacionada](#) · [Debatir](#)

Aryl pyridine as aldosterone synthase inhibitors



www.google.com.co/patents/EP2429995B1?cl=en - Traducir esta página

Otorgada - Presentada el 12/05/2010 - Emitido el 22/01/2014 - Sylvie Chamoin - Novartis AG

The mineralocorticoid hormone **aldosterone** is produced by the adrenal gland and for example tetrahydrofuran or **dioxane**, liquid aromatic hydrocarbons, such as N-((5-(6-chloro-1-methyl-1H-benzo[d]imidazol-2-yl)pyridin-3-yl)methyl) ...

[Descripción general](#) · [Información relacionada](#) · [Debatir](#)

Aryl-pyridine derivatives as aldosterone synthase inhibitors



www.google.com.co/patents/EP2993169B1?cl=en - Traducir esta página

Otorgada - Presentada el 16/11/2010 - Emitido el 20/12/2017 - Martin Allan - Novartis AG

The mineralocorticoid hormone **aldosterone** is produced by the adrenal gland for example tetrahydrofuran or **dioxane**, liquid aromatic hydrocarbons, such as C) and lyophilized to give 1-(3-benzo[b]thiophen-2-yl-pyridin-4-yl)-ethanol ...

[Descripción general](#) · [Información relacionada](#) · [Debatir](#)

Easy search					
3 results for (Pyridin AND benzo AND dioxine AND aldosterone)/CLMS - Collection: FAMPAT					
#	Title	Publ. date	Publication number	1st app. date	Relevanc
1	Spiro-oxindole compounds and their use as therapeutic agents	2010-04-22	WO2010045251	2009-10-13	100 %
2	Renin inhibitors	2007-10-18	WO2007117559	2007-04-05	73 %
3	Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist	2004-10-21	WO2004089415	2004-04-06	60 %

1/1 © EPODOC / EPO

PN - NZ596302 A 20140131

PR - WO2010EP56572 20100512; US20100318413P 20100329; US20090178677P 20090515

AP - NZ20100596302 20100512

DT - I


CCI - C07D213/76

CUI - A61K45/06; A61K31/437; A61K31/44; A61K31/443; A61K31/4439; A61K31/4709; A61K31/542; C07D401/02; C07D401/04; C07D405/04; C07D417/04; C07D471/04; C07D513/04; C07D213/46

PA - NOVARTIS AG

TI - Aryl pyridine as aldosterone synthase inhibitors

AB - 596302 Disclosed herein are compounds of the formula I, wherein the variables are defined in the specification, and their use in the treatment of a disorder or a disease in a subject mediated by **aldosterone** synthase, such as hypokalemia, hypertension, Conn's disease, renal failure, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction, cardiovascular diseases, renal dysfunction, liver diseases, cerebrovascular diseases, vascular diseases, retinopathy, neuropathy, insulinopathy, edema, endothelial dysfunction, baroreceptor dysfunction, migraine headaches, heart failure such as congestive heart failure, arrhythmia, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, impaired diastolic filling, systolic dysfunction, ischemia, hypertrophic cardiomyopathy, sudden cardiac death, myocardial and vascular fibrosis, impaired arterial compliance, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, decreased ejection fraction, cardiac lesions, vascular wall hypertrophy, endothelial thickening and fibrinoid necrosis of coronary arteries. Exemplary embodiments of the compound include the following: N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)ethanesulfonamide; N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)-2,2,2-trifluoroethanesulfonamide; cyclopropanesulfonic acid[5-(3-chloro-4-cyanophenyl)pyridin-3-yl]-amide; (R)-N-((5-(4-cyano-3-fluorophenyl)pyridin-3-yl)(cyclopropyl)methyl) ethanesulfonamide; and N-(cyclopropyl(5-benzo[b]thiophen-2-yl-pyridin-3-yl)methyl) ethanesulfonamide;



Welcome, Olga Rosa Gonzalez FonsecaLayoutSettingsSTN HelpContact UsSign Out

L1

COUNTSRESULTS

DEFULL (0)

EPFULL (25)

FRFULL (0)

GBFULL (0)

INFULL (17)

JPFULL (5)

KRFULL (1)

PCTFULL (46)

Sort by:Publication Date

Display:25

1

JPA (2013); JPB2 (2016) **SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLE AND USE THEREOF AS PHARMACEUTICAL**

PROBLEM TO BE SOLVED: To provide: a compound usable for disorders such as arrhythmia, cardiac failure and cerebral apoplexy caused by disturbance of intracellular calcium homeostasis of sodium-calcium exchanger (NCX), especially sodium-calcium exchanger of subtype 1 (NCX1); production method of ...

2

JPA (2016) **N - (4 - - (-6 - - yl Azaindazole) phenyl) - sulfonamides and their use as a medicament**

N - (4 - phenyl - (Azaindazole - 6 - yl)) - sulfonamides and their use as medicaments according to the present invention, I [Downington 1] Eqn [in the formula, Ar, n, X, Z, R1, R2 and R3 may ...

3

JPA (2010) **5 - An inhibitor activating protein (FLAP) lipoxxygenase**

Is described herein, 5 - lipoxxygenase-activating protein (FLAP) and compounds that modulate the activity of such compounds in pharmaceutical compositions containing them. Respiratory, cardiovascular and other leukotriene-dependent or leukotriene mediated conditions or for treating disease, such FLAP modulators alone or ...

4

JPA (2010) **5 - An inhibitor activating protein (FLAP) lipoxxygenase**

Is described herein, 5 - lipoxxygenase-activating protein (FLAP) and compounds that modulate the activity of such compounds in pharmaceutical compositions containing them. Respiratory, cardiovascular and other leukotriene-dependent or leukotriene mediated conditions or diseases in order to treat, such FLAP modulators ...

5

JPA (2010) **5 - Activating protein (FLAP) inhibitor Iipoxxygenase**

Is described herein which, 5 - lipoxxygenase-activating protein (FLAP) and compounds that modulate the activity of such compounds in pharmaceutical compositions containing them. Respiratory, cardiovascular and other leukotriene-dependent or leukotriene mediated conditions or for treating disease, such FLAP modulators alone ...